More recently, a MET specific inhibitor has been developed, receiving the name tivantinib, which is still in clinical trials for NSCLC, colorectal, prostate and gastric tumors, showing some beneficial effects for the patients but its development still being questioned due to several adverse effects [29–32]. This evidence concerns the gene MET and non-small cell lung carcinoma.